← Leaderboards
Samuel Kent McBrayer
Ut Southwestern Medical Center
$5,142,431
Attributed
$6,408,283
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,408,283 · 6
By mechanism
R01$4,981,384 · 4
P50$932,589 · 1
K22$494,310 · 1
Top collaborators
- Kalil G Abdullah6 shared
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- Margaret A. Phillips$30,430,817
- Kalil G Abdullah$1,835,946
- Milan Rashmin Savani$170,755
- Nathan A Decarolis$27,166
Others in their field
Other Emerging Leaders on “Enzymes”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Jacob Ruff · Cornell University$22,500,000
- Elke Arenholz · Cornell University$14,750,000
- Sacha Gnjatic · Icahn School Of Medicine At Mount Sinai$14,335,772
- Amitinder Kaur · Tulane University Of Louisiana$12,771,713
Research focus
EnzymesCellsMolecularMutationMetabolicBrain NeoplasmsGliomaGenesTumorNovel Therapeutic InterventionIn VivoPre-ClinicalMutantIsocitrate DehydrogenaseMetabolismResponsePyrimidine NucleotidesTreatment StrategyDihydroorotate DehydrogenaseGeneticMouse ModelGlioblastomaNucleotide MetabolismPyrimidine
Grant awards (13)
Development of a nuclear alpha-ketoglutarate biosensor system to study metabolic control of the epigenome$1,792,800
R01 · FY2025 · GM · contact PI
Metabolic mechanisms of glioma progression$682,596
R01 · FY2025 · CA · contact PI
Mechanisms of glioma initiation by IDH oncogenes$656,879
R01 · FY2025 · NS · contact PI
Project 3: Targeting IDH mutant gliomas$447,007
P50 · FY2025 · CA · contact PI
Exploiting Pyrimidine Nucleotide Synthesis Dependence for IDH Mutant Glioma Therapy$375,150
R01 · FY2025 · CA · contact PI
Project 3: Targeting IDH mutant gliomas$485,582
P50 · FY2024 · CA · contact PI
Exploiting Pyrimidine Nucleotide Synthesis Dependence for IDH Mutant Glioma Therapy$356,393
R01 · FY2024 · CA · contact PI
Exploiting Pyrimidine Nucleotide Synthesis Dependence for IDH Mutant Glioma Therapy$367,647
R01 · FY2023 · CA · contact PI
Exploiting Pyrimidine Nucleotide Synthesis Dependence for IDH Mutant Glioma Therapy$375,150
R01 · FY2022 · CA · contact PI
Exploiting Pyrimidine Nucleotide Synthesis Dependence for IDH Mutant Glioma Therapy$374,769
R01 · FY2021 · CA · contact PI
Novel Approaches to Modeling and Treating IDH1 Mutant Glioma$139,364
K22 · FY2021 · CA · contact PI
Novel Approaches to Modeling and Treating IDH1 Mutant Glioma$177,473
K22 · FY2020 · CA · contact PI
Novel Approaches to Modeling and Treating IDH1 Mutant Glioma$177,473
K22 · FY2019 · CA · contact PI